About PetVivo Holdings, Inc.
http://www.petvivo.comPetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses.
CEO
John Lai
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:193.29K
Value:$5.22K
ZEKE CAPITAL ADVISORS, LLC
Shares:25K
Value:$675
Summary
Showing Top 2 of 2
About PetVivo Holdings, Inc.
http://www.petvivo.comPetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $303.28K ▲ | $2.29M ▲ | $-3.01M ▼ | -991.75% ▼ | $-0.11 ▼ | $-1.93M ▲ |
| Q1-2026 | $297.5K ▲ | $2.03M ▼ | $-2.31M ▲ | -776.82% ▲ | $-0.1 ▲ | $-2.06M ▼ |
| Q4-2025 | $224.75K ▼ | $2.26M ▼ | $-2.42M ▼ | -1.08K% ▼ | $-0.12 ▼ | $-1.84M ▼ |
| Q3-2025 | $583.31K ▲ | $2.28M ▼ | $-1.76M ▲ | -301.22% ▲ | $-0.09 ▲ | $-1.7M ▲ |
| Q2-2025 | $200.72K | $2.35M | $-2.18M | -1.08K% | $-0.11 | $-2.14M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $767.91K ▼ | $5.26M ▼ | $1.08M ▼ | $4.18M ▲ |
| Q1-2026 | $3.45M ▲ | $6.89M ▼ | $3.16M ▼ | $3.73M ▼ |
| Q4-2025 | $377.69K ▲ | $9.34M ▲ | $5.12M ▲ | $4.22M ▲ |
| Q3-2025 | $28.89K ▼ | $3.11M ▼ | $3.81M ▲ | $-694.78K ▼ |
| Q2-2025 | $126.24K | $3.19M | $2.78M | $409.17K |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-3.01M ▼ | $-2.19M ▼ | $6.61K ▲ | $-348.08K ▼ | $-2.54M ▼ | $-2.19M ▼ |
| Q1-2026 | $-2.31M ▲ | $-1.63M ▼ | $0 ▲ | $4.71M ▲ | $3.08M ▲ | $-1.63M ▲ |
| Q4-2025 | $-2.42M ▼ | $-1.23M ▼ | $-521.2K ▼ | $1.95M ▲ | $198.8K ▲ | $-1.75M ▼ |
| Q3-2025 | $-1.76M ▲ | $-961.22K ▲ | $-23.63K ▼ | $887.5K ▼ | $-97.35K ▼ | $-984.85K ▲ |
| Q2-2025 | $-2.18M | $-1.6M | $-3.42K | $1.72M | $113.83K | $-1.59M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
John Lai
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:193.29K
Value:$5.22K
ZEKE CAPITAL ADVISORS, LLC
Shares:25K
Value:$675
Summary
Showing Top 2 of 2